Bendamustine in indolent lymphoma: Letting the dust settle down.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42411426.
- Also identified by DOI 10.1002/cncr.70527 and PMC identifier 13372048.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a large population‐based cohort of patients with indolent B‐cell lymphoma, bendamustine–rituximab was not associated with a statistically significant excess risk of secondary primary malignancies compared with cyclophosphamide‐based regimens after adjustment for confounders. These data contextualize prior safety concerns and support thoughtful optimization rather than abandonment of bendamustine‐based frontline therapies in indolent B‐cell lymphomas.